Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD

Inclusion criteria

• ✓. Patients able to understand and willing to sign the informed consent
• ✓. Adult male or female patients with the age of 55 to 85 (inclusive) years who are not employees of the trial sites
• ✓. In sufficiently good health to reasonably expect survival for at least five years after treatment
• ✓. Clinical findings consistent with advanced dry AMD with evidence of one or more areas of ≥1.25 square millimeter of geographic atrophy involving the central fovea
• ✓. Geographic atrophy defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, or FAF
• ✓. The best-corrected visual acuity (BCVA) of the eye to receive the implant will be equal or worse than 20/200 in the first half of the study patients and between 20/80 and 20/400 (inclusive) in the second half of the patients. The BCVA of the eye that is NOT to receive the implant will be better or equal to the eye that will receive the implant
• ✓. Medically suitable to undergo pars plana vitrectomy and the surgical implant procedure, including being able to position post-operatively and use post-operative medications as required
• ✓. Medically suitable for general anesthesia or monitored intravenous sedation, if needed

Exclusion criteria